I think he answers your questions here. Basically

I think he answers your questions here. Basically he's saying that we're to young and small for the market to have faith in both a therapeutics and DX division at this time, thus we're valued at .07-.08 because of the risk reward ratio. By selling off part of the DX it will generate income for both AMBS and shareholders thus bolstering our SP and showing the market we're still mainly focused on Manf, and Phenoguard going forward.

"As described in some detail in previous communications, we are committed to providing a return of capital to our shareholders via a potential spin-out of our Amarantus Diagnostics division. We believe it is important to separate our groundbreaking therapeutics, regenerative medicine and discovery platforms from the diagnostics business, in large part, because the metrics to evaluate these different businesses will create difficulties in the marketplace to unlock the value from each division:

Revenue-focused investors who specialize in diagnostics will view the expenses associated with our therapeutics division as a major distraction and drain on valuable resources;

Science and clinical development focused investors will view the revenue created by our diagnostic assets in the short term as insufficient to support a clinical development company and will question the costs associated to acquire such revenue; and

The management talents required to make each business succeed are quite different ."

- See more at: http://www.thechairmansblog.com/amarantus-bio...Qf1Nz.dpuf